Global Lung Cancer Treatment Market

Lung cancer is the 2nd most common cancer in both men (after prostate) and women (after breast cancer). It is one of the most aggressive cancers and the leading cause of cancer death in the world, more than colon, breast, and prostate cancers combined. According to estimates by the American Cancer Society, approximately 223,000 new cases will be diagnosed and approximately 156,000 people will die of this disease in 2017.

The global lung cancer drugs market was valued at $3.1bn in 2017 and is forecast to grow at a healthy 31.1% CAGR between 2017 and 2023, resulting in 2023 global sales of $20.2bn driven by targeted therapies & strong market uptake of a range of Immuno-(IO) treatments.

Leading commercial immunotherapies (IO) include Bristol Myers’ Yervoy, and Opdivo, Merck’s Keytruda and Roche’s Tecentriq. Bristol, Merck and Roche have only approved therapies in 2nd and 3rd line setting at this stage and are expected to dominate based on their first mover advantage.

AstraZeneca, Pfizer/Merck KGaA have products in advanced stages of trials and pivotal data read out is expected in next 1-2 years.  AstraZeneca is also working on co-formulating durva+treme into a single administration which is believed to provide significant benefits on pricing flexibility in the combo vs mono indications.